Strahlentherapie und Onkologie · 2019 · 43 citations · 33 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy For Thoracic MalignanciesNatural Killer Cell TherapyCar-nk Cell TherapyCombination Cell TherapyCombination ImmunochemotherapyImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyNon-small Cell Lung Cancer ImmunotherapyProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 Inhibitors
Membrane heat shock protein 70 (mHsp70) is indicative of high-risk tumors and serves as a tumor-specific target for natural killer (NK) cells stimulated with Hsp70 peptide (TKD) and Interleukin(IL)-2. Radiochemotherapy (RCT), mHsp70-targeting NK cells, and programmed death(PD)-1 inhibition were combined to improve the efficacy of tumor-specific immune cells in a non-small cell lung carcinoma (NSCLC) patient. Following simultaneous RCT (64.8 Gy), a patient with inoperable NSCLC (cT4, cN3, cM0, stage IIIb) was treated with 4 cycles of autologous ex vivo TKD/IL-2-activated NK cells and the PD-1 antibody nivolumab as a second-line therapy. Blood samples were taken for immunophenotyping during the course of therapy. Adoptive transfer of ex vivo TKD/IL-2-activated NK cells after RCT combined with PD-1 blockade is well tolerated and results in superior overall survival (OS). No viable tumor cells but a massive immune cell infiltration in fibrotic tissue was detected after therapy. Neither tumor progression nor distant metastases were detectable by CT scanning 33 months after diagnosis. Therapy response was associated with significantly increased CD3 − /NKG2D + /CD94 + NK cell counts, elevated CD8 + to CD4 + T cell and CD3 − /CD56 bright to CD3 − /CD56 dim NK cell ratios, and significantly reduced regulatory T cells (Tregs) in the peripheral blood. A combined therapy consisting of RCT, mHsp70-targeting NK cells, and PD-1 antibody inhibition is well tolerated, induces anti-tumor immunity, and results in long-term tumor control in one patient with advanced NSCLC. Further, randomized studies are necessary to confirm the efficacy of this combination therapy.
33
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text
Julie R. Brahmer, Charles G. Drake, Ira Wollner et al. · Journal of Clinical Oncology · 2010 · 2.9K citations · Full text
Medicine, Oncology, Pharmacology +17
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text